- Project Biohacking Newsletter
- Posts
- The BPC-157 headline you read wrong
The BPC-157 headline you read wrong
April's removal was real. What it means is the opposite of what most people think.
Jeffrey Nunn
June 03, 2026
Hey biohackers,
In April, the FDA quietly pulled BPC-157 off its restricted list. The internet read that as a green light. Half the peptide accounts you follow basically threw a party.
They read it wrong.
Affiliate Disclosure: This newsletter contains affiliate links. When you purchase through these links using code PROBIO15, I may earn a commission at no additional cost to you. I only recommend vendors I personally use and trust.
Here is the line nobody put in the headline. Leaving the restricted list and becoming legal to compound are two separate actions. Only the first one happened. BPC-157 is off the restricted list. It has not been added to the list a pharmacy is actually allowed to compound from.
Those are different documents. Different decisions. And the space between them is the entire story.
Think of it this way. Getting your name removed from a no-fly list does not hand you a boarding pass. It only means you are allowed to start the process of earning one. For a peptide, that process is long and slow on purpose.
Here is what BPC-157 still has to clear. An FDA advisory committee has to review it. The agency has to accept that recommendation. Then it publishes a proposed rule, opens a public comment window, reads the comments, and issues a final rule. Each step takes months.
Under normal timelines that is more than a year of work after the committee even meets. The committee meets in late July 2026. Run the math and the earliest realistic window for legally compounded BPC-157 lands somewhere in mid to late 2027.
So when a clinic or a glossy telehealth page tells you they can fill your BPC-157 script this week, they are not describing a loophole. They are describing a compliance problem they have decided to ignore.
And it is not just BPC-157. The same holding pattern covers the whole group that left Category 2 in April. TB-500. KPV. MOTs-C. Semax. Epitalon. Every one of them sits in the same spot. Off one list, not yet on the other, waiting on a process that has barely begun.
It helps to understand the actual test. A peptide is only compoundable if it clears one of three gates. It is on the FDA's official Bulks List, or it is a component of an approved drug, or it has a published quality standard in the U.S. Pharmacopeia. That is it. A prescription does not override the test. A reputable pharmacy does not override the test. Right now the April peptides clear none of the three.
There is one quiet exception worth knowing, because it cuts the other way. Non-injectable GHK-Cu, the topical and cosmetic form, actually got more accessible this spring and landed back in the eligible category. One peptide moved forward. The headline names stayed stuck.
If you want a preview of how the stuck ones play out, look at the GLP-1 story. Compounded semaglutide and tirzepatide were everywhere in 2023 and 2024, riding a temporary shortage exception. The shortages resolved. The exception closed. And the FDA did not ease into it.
In the twelve months ending March 2026, the agency sent more than 80 warning letters to telehealth companies over compounded GLP-1 marketing. Thirty of them landed on a single day. The pattern was consistent. Same-as-the-real-drug claims. Vague sourcing. Outcome promises with nothing behind them.
The lesson is simple. When a temporary lane closes, enforcement shows up fast, and the marketing language is the first thing they read. Any peptide that eventually reaches eligibility inherits those exact same rules.
It is worth knowing what the scramble looks like, because the April removals set off a wave of it. Watch for "research use only" labels stapled onto consumer marketing. Watch for salt-form swaps dressed up as a workaround. Watch for offshore checkout and "same as Ozempic" language. None of it changes the underlying status. All of it tends to draw attention eventually.
Now here is the part the panic-posters keep missing.
The compounding pharmacy lane was never the only road. For a huge slice of the peptide world it was never even the main one. Compounding rules and chemical-supplier rules are two completely different worlds, governed by two completely different frameworks. The pharmacy pathway is frozen until 2027. The research peptide vendor world is not waiting on any of it.
That is where serious researchers have been sourcing all along. And the thing that matters in that world is not which government list a molecule sits on this month. It is purity. It is whether the vendor publishes real, per-batch testing. It is whether the certificate of analysis is a document you can actually read instead of a promise that one exists somewhere.
That filter is the whole game. Verified third-party testing. HPLC results per lot. A catalog that does not hide behind vague language. Get those three right and the regulatory noise swirling around pharmacies stops being your problem at all.
This is also where the confusion becomes an edge. While most people argue about pharmacy legality they do not understand, the researchers who get the distinction are quietly stocking from vendors that test every lot and stand behind the numbers.
That is exactly why we keep pointing readers to vendors that publish their testing and stand behind the numbers. While the pharmacy lane stays frozen, this is the lineup we trust, and right now you can stack our code on top at every one of them. Use PROBIO15 at checkout for an extra 15 percent off.
Shop our top rated vetted peptide vendor with code PROBIO15:
Biolongevity Labs → View Full Catalog
Read the full breakdown → https://www.projectbiohacking.com/guide-to-compounding-pharmacy-peptides
The headlines will keep getting this one wrong. You do not have to. Knowing the difference between off the list and on the list is the kind of edge that quietly compounds.
Project Biohacking Resources
Some links may be affiliate links; I may earn a small commission at no extra cost to you. I only recommend vendors I use and trust, Biolongevity Labs!
👇🏻Supplements Affiliates👇🏻
Your body isn't broken — it's just been starved of the right nutrients. Clive de Carle's complete line of natural health essentials gives it exactly what it needs.
👇🏻Lab Affiliatess👇🏻
Guides
🔚 Outro & Final Thoughts
The headlines will keep getting this one wrong, treating "off the restricted list" like a green light when the legal lane stays frozen until 2027. Knowing the difference between off the list and on the list is the kind of quiet edge that separates the researchers who get burned from the ones who do not. Read carefully, source carefully, and let everyone else chase the noise.
Until next time, stay ahead of your age!
– Jeff
Founder, Project Biohacking
Affiliate & Earnings Disclosure
Project Biohacking participates in affiliate partnerships with select peptide vendors. When you make purchases through the links provided in this newsletter or use discount code PROBIO15, I may receive a commission at no extra cost to you.
These affiliate relationships do not influence my recommendations, I only promote products and vendors I personally use, have researched thoroughly, and believe provide value to the biohacking community. All opinions expressed are my own based on personal experience and research.
Your support through these affiliate links helps fund the research, testing, and content creation that makes Project Biohacking possible.
Disclaimer: I’m here to share what I’ve learned, not to replace your doctor. Always check with a qualified healthcare provider before trying anything new. And yes, peptides are often for research use only; please don’t turn your kitchen into a chemistry lab without supervision.